Leerink Partnrs Brokers Lift Earnings Estimates for Revvity

Revvity Inc. (NYSE:RVTY) – Equities research analysts at Leerink Partnrs upped their Q2 2025 earnings estimates for Revvity in a report issued on Thursday, July 17th. Leerink Partnrs analyst P. Souda now expects that the company will post earnings per share of $1.15 for the quarter, up from their previous estimate of $1.14. The consensus estimate for Revvity’s current full-year earnings is $4.94 per share. Leerink Partnrs also issued estimates for Revvity’s FY2025 earnings at $4.94 EPS.

Revvity (NYSE:RVTY) last announced its earnings results on Monday, April 28th. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.96 by $0.05. The business had revenue of $664.76 million for the quarter, compared to analyst estimates of $662.30 million. Revvity had a return on equity of 7.73% and a net margin of 10.35%. Revvity’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.98 EPS.

Other analysts also recently issued reports about the company. Raymond James Financial reiterated an “outperform” rating and set a $120.00 target price (down from $145.00) on shares of Revvity in a research report on Tuesday, April 29th. UBS Group raised Revvity from a “neutral” rating to a “buy” rating and lowered their price target for the stock from $145.00 to $115.00 in a report on Thursday, May 1st. Bank of America lowered their price target on Revvity from $116.00 to $110.00 and set a “buy” rating for the company in a report on Thursday, June 26th. Barclays lowered their price target on Revvity from $140.00 to $110.00 and set an “overweight” rating for the company in a report on Thursday, April 10th. Finally, Wall Street Zen raised Revvity from a “hold” rating to a “buy” rating in a report on Saturday, June 28th. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $123.07.

Revvity Stock Performance

RVTY opened at $96.22 on Friday. The business has a fifty day simple moving average of $95.06 and a 200 day simple moving average of $104.10. The company has a market capitalization of $11.34 billion, a PE ratio of 40.97, a price-to-earnings-growth ratio of 2.39 and a beta of 0.98. Revvity has a 1 year low of $87.70 and a 1 year high of $129.50. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.58 and a quick ratio of 2.99.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 8th. Shareholders of record on Friday, July 18th will be paid a dividend of $0.07 per share. The ex-dividend date is Friday, July 18th. This represents a $0.28 annualized dividend and a yield of 0.29%. Revvity’s dividend payout ratio is 11.91%.

Hedge Funds Weigh In On Revvity

Several hedge funds and other institutional investors have recently modified their holdings of the company. Raymond James Financial Inc. bought a new position in Revvity in the 4th quarter worth $2,248,000. HighTower Advisors LLC increased its stake in Revvity by 21.1% in the 4th quarter. HighTower Advisors LLC now owns 6,415 shares of the company’s stock worth $716,000 after buying an additional 1,117 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in Revvity by 33.5% in the 4th quarter. EverSource Wealth Advisors LLC now owns 522 shares of the company’s stock worth $58,000 after buying an additional 131 shares in the last quarter. Natixis Advisors LLC increased its stake in Revvity by 14.7% in the 4th quarter. Natixis Advisors LLC now owns 14,339 shares of the company’s stock worth $1,600,000 after buying an additional 1,840 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. increased its stake in Revvity by 40.7% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 4,102 shares of the company’s stock worth $458,000 after buying an additional 1,186 shares in the last quarter. 86.65% of the stock is owned by institutional investors.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.